含有雷帕格林化物和二化黄素的基托桑基水凝:对结构完整性,药物释放和抗菌活性的影响
Yasir Qasim Almajidi1, Maher Abdulrazzaq Al-Hakeem1, Marwah Suliman Maashi2,3
1Department of Pharmaceutics, College of Pharmacy, Alnahrain University, Baghdad, Iraq.
Naunyn-Schmiedeberg's archives of pharmacology
|November 4, 2025
概括
装载着雷帕格林化和二化黄素的新型奇托桑水凝对糖尿病足 (DFU) 有希望. 这些热敏带提供增强的生物相容性,强大的抗菌作用,并控制药物释放以改善伤口愈合.
科学领域:
- 生物材料科学 生物材料科学
- 伤口愈合 治愈 伤口愈合
- 药物运输 药物运输 药物运输
背景情况:
- 糖尿病足 (DFU) 由于慢性感染和愈合障碍,具有重大临床挑战.
- 目前的治疗方法往往无法解决DFU的多面性质,包括感染,氧化应激和再生.
- 需要新的伤口带来同时管理这些复杂的病理因素.
研究的目的:
- 开发和表征热敏的基托基水凝,同时加载有雷帕格林化物 (Ripa) 和二化黄素 (dfCur).
- 为了评估这些双药水凝的物理化学特性,抗菌疗效和细胞兼容性,用于DFU管理.
- 研究这种协同配方在先进伤口护理中的潜力.
主要方法:
- 酸盐水凝与β-糖酸盐合成,并加载Ripa,dfCur或两者.
- 使用FESEM,ATR-FTIR,重力测量方法和UV-Vis光谱测量,评估了物理化学特性 (形态,化学,胀,多孔性,降解,药物释放).
- 使用NIH3T3纤维细胞的MTT测定来评估细胞相容性,并测试抗菌活性针对金黄色葡萄球菌和大肠杆菌.
主要成果:
- 双药水凝显示出高胀能力 (约115%) 和快速降解 (在28日保持46-48%的质量).
- 在7天内观察到Ripa和dfCur的持续释放.
- 纤维细胞活力的显著增强 (128.4 ± 3.2%) 和强烈的抗菌活性针对S. aureus (21.6 ± 1.4毫米抑制区) 和大肠杆菌 (19.3 ± 1.2毫米抑制区) 记录.
结论:
- 将Ripa和dfCur同时加载到热敏的基托水凝中,可以创建一个协同平台,提高生物相容性和抗菌性能.
- 开发的水凝系统提供了可控的药物释放,使其成为糖尿病足管理的有前途的多功能.
- 需要进一步的体内研究来验证这种先进的伤口带的治疗潜力.
更多相关视频
05:26Fabrication of Size-Controlled and Emulsion-Free Chitosan-Genipin Microgels for Tissue Engineering Applications
Published on: April 13, 2022
3.9K
08:59A Freeze-Thawing Method to Prepare Chitosan-Polyvinyl alcohol Hydrogels Without Crosslinking Agents and Diflunisal Release Studies
Published on: January 14, 2020
18.9K
相关概念视频
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
188
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
188
01:06Oral Hypoglycemic Agents: Glinides
585
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
585